Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

What's In The Cards For Centene (CNC) This Earnings Season?

Published 04/19/2017, 09:49 PM
Updated 07/09/2023, 06:31 AM

Centene Corporation (NYSE:CNC) will release first-quarter 2017 results on Apr 25, before the market opens. Last quarter, the company posted a positive earnings surprise of 6.25%. Let’s see how things are shaping up for this announcement.

Factors to be Considered this Quarter

Centene’s acquisition of Health Net in the last reported quarter is expected to have boosted its top line this time around.

The company’s new Medicaid contracts are likely have boosted the membership, in turn, bolstering revenue growth in the to-be-reported quarter.

The company also started Medicare Advantage plans in four new states in Jan 2017, which is likely to have contributed to revenue growth.

The company also remains committed toward enhancing shareholders’ value. To this end, it undertook share repurchases, which should impact the bottom line positively by reducing the outstanding share count.

However, the company’s merger with Health Net resulted in incurring substantial costs, which are likely to put pressure on the bottom line.

Health Net’s high Selling General and Administrative expenses are also expected to have increased its overallexpenses, limiting bottom-line growth.

Increasing costs related to extinguishment of debt, reserves for settlements, legal judgments and lawsuits, impairments of long-lived assets are anticipated to have affected earnings.

Earnings Whispers

Our proven model does not conclusively show that Centene is likely to beat on earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here as you will see below.

Zacks ESP: Centene has an Earnings ESP of -1.89%. This is because the Most Accurate estimate is pegged at $1.04, while the Zacks Consensus Estimate stands at $1.06. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Zacks Rank: Centene carries a Zacks Rank #3. Though the company has a favorable Zacks Rank, its negative Earnings ESP complicates surprise prediction.

We caution against Sell-rated stocks (Zacks Rank #4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.

Stocks to Consider

Here are some other companies from the medical sector that you may want to consider as these have the right combination of elements to post an earnings beat this quarter:

Amgen, Inc. (NASDAQ:AMGN) , which is set to report first-quarter earnings on Apr 26, has an Earnings ESP of +1.99% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.

Anthem, Inc. (NYSE:ANTM) has an Earnings ESP of +7.79% and a Zacks Rank #2. The company is set to report first-quarter earnings on Apr 26.

Humana, Inc. (NYSE:HUM) has an Earnings ESP of +2.06% and a Zacks Rank #2 The company is set to report first-quarter earnings on May 3.

Zacks' 2017 IPO Watch List

Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.

One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this IPO Watch List today for free >>



Amgen Inc. (AMGN): Free Stock Analysis Report

Humana Inc. (HUM): Free Stock Analysis Report

Anthem, Inc. (ANTM): Free Stock Analysis Report

Centene Corporation (CNC): Free Stock Analysis Report

Original post

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.